CN109917137A - 低离子增强液的制备方法 - Google Patents

低离子增强液的制备方法 Download PDF

Info

Publication number
CN109917137A
CN109917137A CN201910190758.9A CN201910190758A CN109917137A CN 109917137 A CN109917137 A CN 109917137A CN 201910190758 A CN201910190758 A CN 201910190758A CN 109917137 A CN109917137 A CN 109917137A
Authority
CN
China
Prior art keywords
preparation
low ion
enhancement solution
mmol
ion enhancement
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201910190758.9A
Other languages
English (en)
Inventor
陈玉平
陈芳芳
王布强
孙玲
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Bo Medicine Biotechnology Ltd By Share Ltd
Original Assignee
Jiangsu Bo Medicine Biotechnology Ltd By Share Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Bo Medicine Biotechnology Ltd By Share Ltd filed Critical Jiangsu Bo Medicine Biotechnology Ltd By Share Ltd
Priority to CN201910190758.9A priority Critical patent/CN109917137A/zh
Publication of CN109917137A publication Critical patent/CN109917137A/zh
Pending legal-status Critical Current

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

本发明涉及低离子增强液的制备方法,它包括缓冲液的配制和低离子增强液的配制。本发明低离子增强液制备方法,能够制备出新型增强介质,可以促进红细胞抗体与抗原更快地结合,减少孵育时间,优化加快凝胶法间接抗人球蛋白试验的检测流程。

Description

低离子增强液的制备方法
技术领域
本发明涉及低离子增强液的制备方法。
背景技术
输血发展史上里程碑事件是1900年奥地利维也纳大学科学家KarlLandersteiner等发现了A、B、O血型。两年后,他的学生又发现了AB型血型,从而开创了安全输血的新时代,Landersteiner也因此于1930年获得了诺贝尔医学奖。1927~1947年间相继发现MNS、P和Rh系统,安全的输血技术才得以初步建立。
临床有效用血首先要求临床医生明确哪些患者在何种情况下需要输血,有效治疗凝血障碍和防止输血的不良反应,交叉配血是国家《临床输血技术规范》中明确要求检查的项目,交叉配血不合时必须按有关规定做抗体筛选试验,这对于保障输血安全、提高输血治疗效果、减少输血不良反应起到了非常重要的作用。抗人球蛋白试验是检测IgG抗体的金标准方法,间接抗人球蛋白试验是检测IgG抗体的有效方法,目前临床在用的绝大多数属于凝胶法抗人球蛋白试验,该方法采用的增强液是LISS液,虽然已经将经典盐水37℃孵育的时间从30~60分钟缩短到15分钟,但对于临床尤其是急救情况下,时间显得尤为重要,15分钟仍然太长。
发明内容
本发明所要解决的技术问题是针对上述现有技术提供低离子增强液的制备方法,缩短了孵育时间,提高了特异性和灵敏度 。
本发明的目的是这样实现的:
一种低离子增强液的制备方法,包括以下几个步骤:
步骤一、缓冲液的配方如下:
磷酸二氢钾 (130-180)mmol
磷酸氢二钠 (130-180)mmol
以上试剂用纯化水分别溶解;
步骤二、低离子增强液的配方如下:
(130-180)mmol磷酸二氢钾 (10-12)x10-3ml/ml
(130-180)mmol磷酸氢二钠 (7-10)x10-3ml/ml
氯化钠 (1.6-1.9)x10-3g/ml
甘氨酸 (15-20)x10-3g/ml
对羟基苯甲酸甲酯 (5-9)x10-4g/ml
对羟基苯甲酸丙脂 (0. 8-1.5)x10-4g/ml
牛血清白蛋白 (1-4)x10-3g/ml
以上试剂用纯化水溶解,调节pH为6.4-7.0。
与现有技术相比,本发明的优点在于:对羟基苯甲酸甲酯和对羟基苯甲酸丙脂所具有的酚羟基结构,可以破坏微生物的细胞膜,使细胞内的蛋白值变相,有效抑制微生物的生长,防止凝胶或抗体因为细菌繁殖而失效;牛血清白蛋白带有正电荷,能中和细胞表面的负电荷,降低红细胞表面电荷量,减少红细胞之间的排斥力,缩短红细胞之间距离,同时也具有强亲水性,可破坏红细胞表面亲水层,降低抗体结合红细胞抗原时所产生的空间排斥效应,所以在保障特异性和灵敏度的前提下能缩短37℃孵育时间;低离子液提供的低离子环境可以增加带正电荷的抗体与带有负电荷的抗原相互碰撞产生特异性结合形成抗原抗体复合体的机会,促进抗体与抗原结合效率,缩短抗原抗体结合的时间。因此可以加速抗体与红细胞上相应抗原的结合,同时提高抗原与抗体尤其是IgG的反应强度,进一步减少试验孵育时间,提高凝集效果。

Claims (2)

1.低离子增强液的制备方法,其特征在于:
所述制备方法包括以下几个步骤:
步骤一、缓冲液的配制
磷酸二氢钾 (130-180)mmol
磷酸氢二钠 (130-180)mmol
步骤二、低离子增强液的配方如下:
(130-180)mmol磷酸二氢钾 (10-12)x10-3ml/ml
(130-180)mmol磷酸氢二钠 (7-10)x10-3ml/ml
氯化钠 (1.6-1.9)x10-3g/ml
甘氨酸 (15-20)x10-3g/ml
对羟基苯甲酸甲酯 (5-9)x10-4g/ml
对羟基苯甲酸丙脂 (0. 8-1.5)x10-4g/ml
牛血清白蛋白 (1-4)x10-3g/ml
以上试剂用纯化水溶解,调节pH为6.4-7.0。
2.以上述试剂中的一种或几种配制而成的用于抗人球蛋白试验,达到缩短了孵育时间,提高了特异性和灵敏度目的的均属该专利包含的范围 。
CN201910190758.9A 2019-03-13 2019-03-13 低离子增强液的制备方法 Pending CN109917137A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910190758.9A CN109917137A (zh) 2019-03-13 2019-03-13 低离子增强液的制备方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910190758.9A CN109917137A (zh) 2019-03-13 2019-03-13 低离子增强液的制备方法

Publications (1)

Publication Number Publication Date
CN109917137A true CN109917137A (zh) 2019-06-21

Family

ID=66964694

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910190758.9A Pending CN109917137A (zh) 2019-03-13 2019-03-13 低离子增强液的制备方法

Country Status (1)

Country Link
CN (1) CN109917137A (zh)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1840572A1 (en) * 2006-03-30 2007-10-03 Stiftung Für Diagnostische Forschung A system for the enhancement of the detection of antibodies directed against red cell antigens
CN101718786A (zh) * 2009-11-25 2010-06-02 江阴力博医药生物技术有限公司 抗人球蛋白交叉配血卡的制备方法
CN108548921A (zh) * 2018-03-13 2018-09-18 中国人民解放军第二军医大学第二附属医院 一种间接抗人球蛋白加速配血的试验方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1840572A1 (en) * 2006-03-30 2007-10-03 Stiftung Für Diagnostische Forschung A system for the enhancement of the detection of antibodies directed against red cell antigens
CN101718786A (zh) * 2009-11-25 2010-06-02 江阴力博医药生物技术有限公司 抗人球蛋白交叉配血卡的制备方法
CN108548921A (zh) * 2018-03-13 2018-09-18 中国人民解放军第二军医大学第二附属医院 一种间接抗人球蛋白加速配血的试验方法

Similar Documents

Publication Publication Date Title
Henson et al. The release of granule enzymes from human neutrophils stimulated by aggregated immunoglobulins of different classes and subclasses
Junod Metabolism, production, and release of hormones and mediators in the lung
Petty et al. Secondary effect of aldosterone on Na-KATPase activity in the rabbit cortical collecting tubule.
Karlsson et al. Insulin induces translocation of glucose transporter GLUT4 to plasma membrane caveolae in adipocytes
Dorion et al. Risk and clinical significance of developing antibodies induced by topical thrombin preparations
Wang et al. Activated IL-23/IL-17 pathway closely correlates with increased Foxp3 expression in livers of chronic hepatitis B patients
Ding et al. The development of a new bioartificial liver and its application in 12 acute liver failure patients
Craven et al. Brain hexokinase: the preparation of inner and outer mitochondrial membranes
DE202020105116U1 (de) Reagenzien und Verwendungen zur Diagnose einer SARS-CoV-2-Infektion
Lichter Chimpanzee antibodies to Australia antigen
DE202020105117U1 (de) Reagenzien und Verwendungen zur Diagnose einer SARS-CoV-2-Infektion
JPS6270321A (ja) 動物の生長促進方法
Jesus et al. Ultrasonic-based membrane aided sample preparation of urine proteomes
Song et al. BKCa channels regulate the immunomodulatory properties of WJ-MSCs by affecting the exosome protein profiles during the inflammatory response
Cavelti Autoimmunologic disease
JP2651943B2 (ja) 動物細胞膜に蛋白質を挿入する方法
Tanimoto et al. Immunohistochemical localization of antigen presenting cells in liver from patients with primary biliary cirrhosis; highly restricted distribution of CD83-positive activated dendritic cells
CN102441363A (zh) 一种用于清除血液中癌细胞的吸附剂
CN109917137A (zh) 低离子增强液的制备方法
US4618588A (en) Reagent and merchandising kit for use in the diagnosis of syphilis and preparation thereof
Ip Effect of partial hepatectomy and hydrocortisone administration on liver and serum sialyltransferase activities
Wahl et al. Effects of kininase II inhibitors on the vasomotor response to bradykinin of feline intracranial and extracranial arteries in vitro and in situ
D'Alesandro et al. Changes in lactic dehydrogenase levels of Trypanosoma lewisi associated with appearance of ablastic immunity
CN102183657B (zh) 一种依赖聚苯乙烯纳米粒大幅度增加化学发光磁酶免疫灵敏度的方法
PL110972B1 (en) Method of determination of hormones or drugs total content

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20190621